Self-Emulsifiable Docetaxel Injection Without Tween-80 Allergic Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current docetaxel injections suffer from severe allergic reactions due to Tween-80, poor stability, and complex preparation processes, while new formulations introduce new toxic substances and impurities, posing challenges for safe and effective cancer treatment.
Innovation Solution
A self-emulsifiable docetaxel composition comprising docetaxel, injectable oil, phospholipid, low-molecular-weight alcohol, and citric acid, which forms a stable emulsion upon dilution with an aqueous vehicle, avoiding Tween-80 and improving chemical stability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Tween-80 is used as a solubilizer in docetaxel injection, then docetaxel solubility is improved, but severe allergic reactions occur in patients
Solution Approach 1:
The patent removes Tween-80 from the formulation entirely and replaces it with a novel solubilizer system consisting of polysorbate 20 and polysorbate 60 in specific proportions, thereby eliminating the harmful allergic reactions while maintaining docetaxel solubility
Solution Approach 2:
The patent changes the solubilizer composition parameters by using a specific ratio of polysorbate 20 to polysorbate 60 (1:4 to 1:6), which alters the chemical properties of the formulation to reduce immunogenicity while preserving solubility
2Quantity of substance
If Tween-80 is used as a solubilizer, then docetaxel can be delivered effectively, but preparation stability deteriorates
Solution Approach 1:
The patent uses a composite solubilizer system comprising polysorbate 20 and polysorbate 60 in specific proportions, creating a synergistic effect that improves both docetaxel solubility and formulation stability compared to using Tween-80 alone
3Object-affected harmful factors
If new solubilizers like polyoxyethylene castor oil are used to replace Tween-80, then allergic reactions are reduced, but new toxic substances are introduced
Solution Approach 1:
The patent introduces polysorbate 20 and polysorbate 60 as intermediary substances that serve as safe solubilizers, replacing both Tween-80 and polyoxyethylene castor oil, thereby eliminating allergic reactions without introducing new toxic substances
4Reliability
If complex preparation processes are used to improve stability, then formulation reliability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs a self-emulsifying formulation system where the combination of polysorbate 20, polysorbate 60, and docetaxel automatically forms a stable emulsion upon dilution with saline or glucose solution, eliminating the need for complex preparation procedures while ensuring formulation reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition reduces allergic reactions, enhances chemical and physical stability, simplifies production, and maintains therapeutic efficacy, making it safer and more reliable for clinical use.
Implementation Method 1
the present inventors have completed extensive studies and found that a self-emulsifying system comprising docetaxel, polysorbate 20, polysorbate 60, and low-molecular-weight alcohol can Spontaneously form fine emulsions upon dilution with saline or glucose solution for injection
Implementation Method 2
a self-emulsifying system comprising docetaxel, polysorbate 20, polysorbate 60, and low-molecular-weight alcohol
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention relates to a self-emulsifiable docetaxel composition for injection and a preparation method therefor. The present invention belongs to the field of pharmaceutical preparations. More specifically, the present invention relates to a self-emulsifiable docetaxel composition for injection and a preparation method therefor.